Drugs / Cross-Linked Polyelectrolyte (CLP)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01944007 | Dec 2007 → Mar 2008 | — | Sorbent Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cross-Linked Polyelectrolyte (CLP) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01944007 ↗ |
| Known as | CLP | “CLP is an orally administered, non-absorbed, superabsorbent polymer being developed to increase fecal excretion of sodium, potassium and water in patients with heart failure...” PMID 24460668 ↗ Jan 2014 |
| Modality | Other / unclassified | “CLP is an orally administered, non-absorbed, superabsorbent polymer” PMID 24460668 ↗ Jan 2014 |
| Route | Oral | “CLP was administered orally” NCT01944007 ↗ |